CA3054817A1 - Methods and compositions for delivering mycophenolic acid active agents to non-human mammals - Google Patents

Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Download PDF

Info

Publication number
CA3054817A1
CA3054817A1 CA3054817A CA3054817A CA3054817A1 CA 3054817 A1 CA3054817 A1 CA 3054817A1 CA 3054817 A CA3054817 A CA 3054817A CA 3054817 A CA3054817 A CA 3054817A CA 3054817 A1 CA3054817 A1 CA 3054817A1
Authority
CA
Canada
Prior art keywords
release
mpa
modified
veterinary
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3054817A
Other languages
English (en)
French (fr)
Inventor
Michael KLOTSMAN
Padmaja Shivanand
Wayne H. Anderson
Gayatri Sathyan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Okava Pharmaceuticals Inc
Original Assignee
Okava Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Okava Pharmaceuticals Inc filed Critical Okava Pharmaceuticals Inc
Publication of CA3054817A1 publication Critical patent/CA3054817A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3054817A 2017-03-13 2018-03-13 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals Pending CA3054817A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762470806P 2017-03-13 2017-03-13
US62/470,806 2017-03-13
US201762503270P 2017-05-08 2017-05-08
US62/503,270 2017-05-08
PCT/US2018/022266 WO2018170022A2 (en) 2017-03-13 2018-03-13 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals

Publications (1)

Publication Number Publication Date
CA3054817A1 true CA3054817A1 (en) 2018-09-20

Family

ID=61911669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054817A Pending CA3054817A1 (en) 2017-03-13 2018-03-13 Methods and compositions for delivering mycophenolic acid active agents to non-human mammals

Country Status (10)

Country Link
US (4) US11633378B2 (https=)
EP (1) EP3595639A2 (https=)
JP (1) JP7385474B2 (https=)
KR (1) KR20190131036A (https=)
CN (1) CN110662533A (https=)
AU (1) AU2018236225B2 (https=)
BR (1) BR112019019003A2 (https=)
CA (1) CA3054817A1 (https=)
MX (1) MX2019010829A (https=)
WO (1) WO2018170022A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633378B2 (en) 2017-03-13 2023-04-25 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
JP2022506007A (ja) * 2018-09-07 2022-01-17 オカヴァ ファーマシューティカルズ， インコーポレイテッド ミコフェノール酸活性剤を非ヒト哺乳動物に送達するための方法および組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US5049394A (en) 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
GB0419355D0 (en) 2004-08-31 2004-09-29 Novartis Ag Organic compounds
CN1994295A (zh) 2006-01-06 2007-07-11 华北制药集团新药研究开发有限责任公司 霉酚酸盐的包有肠溶衣的药物组合物
WO2008090569A1 (en) * 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
JP2011513391A (ja) * 2008-03-05 2011-04-28 パナセア バイオテック リミテッド ミコフェノラートを含有する徐放性医薬組成物およびその方法
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
KR20110091252A (ko) * 2010-02-05 2011-08-11 서울대학교산학협력단 미코페놀레이트 모페틸을 함유한 서방성 면역 억제제
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
US11633378B2 (en) 2017-03-13 2023-04-25 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals

Also Published As

Publication number Publication date
KR20190131036A (ko) 2019-11-25
BR112019019003A2 (pt) 2020-04-14
AU2018236225B2 (en) 2023-11-30
US20240299343A1 (en) 2024-09-12
WO2018170022A3 (en) 2018-11-08
MX2019010829A (es) 2020-02-05
US20250049753A1 (en) 2025-02-13
CN110662533A (zh) 2020-01-07
US20190201375A1 (en) 2019-07-04
JP7385474B2 (ja) 2023-11-22
EP3595639A2 (en) 2020-01-22
JP2020510691A (ja) 2020-04-09
AU2018236225A1 (en) 2019-09-19
WO2018170022A2 (en) 2018-09-20
US20200030285A1 (en) 2020-01-30
US11633378B2 (en) 2023-04-25
US11786505B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
RS77904A (sr) Oblik za oralnu primenu teško rastvornih baznih delotvornih supstanci
CA2616081C (en) Gastroretentive formulations and manufacturing process thereof
JP2008303223A (ja) 脈動用量薬剤経口送達システム
US20240299343A1 (en) Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
JP2003514019A (ja) カルベジロールメタンスルホン酸塩
PL212566B1 (pl) Sól estru etylowego kwasu 3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo) fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego
PL188834B1 (pl) Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
JP2019512537A (ja) ダパグリフロジンの医薬組成物
JP2005521682A (ja) 結腸放出組成物
KR20190064215A (ko) 토파시티닙을 포함하는 약제학적 조성물
WO2011051967A2 (en) Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
US20140255484A1 (en) Modified release pharmaceutical compositions of dexlansoprazole
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
EP2968179B1 (en) Controlled release pharmaceutical dosage forms
HU182577B (en) Process for producing pharmaceutical compositions of improved biological activity containing ergot-alkaloides
WO2021204883A1 (fr) Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2021186354A1 (en) Controlled-release pharmaceutical formulations for treatment of intestinal infections
AU2016280148A1 (en) Extended release Capecitabine capsules
CA3111908A1 (en) Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
Singh et al. Development of biphasic pulsatile release mini-tablets system of poorly water soluble carvedilol phosphate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220919

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250116

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250516

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106